CCL22 and ovarian cancer: Although there is evidence that CCL22 found in ovarian cancers, serves to attract CCR4+ Treg cells, we found no evidence for expression of its major ligands CCL22 or CCL17 in the fibrosarcomas described herein.13 However, some reports indicate that CCR4 may bind other inflammatory chemokines such as CCL5 and CCL2,24 so expression of the receptor was analysed on both tumour-infiltrating Foxp3− and Foxp3+ T cells.